Latest Insider Transactions at Oramed Pharmaceuticals Inc. (ORMP)
This section provides a real-time view of insider transactions for Oramed Pharmaceuticals Inc. (ORMP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ORAMED PHARMACEUTICALS INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ORAMED PHARMACEUTICALS INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 31
2021
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
33,333
+24.39%
|
-
|
|
Aug 31
2021
|
Miriam Kidron Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,666
+32.0%
|
-
|
|
Aug 09
2021
|
Nadav Kidron President and CEO |
SELL
Open market or private sale
|
Direct |
220,000
-25.33%
|
$4,400,000
$20.11 P/Share
|
|
Aug 09
2021
|
Kevin Rakin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
26,093
-10.82%
|
$547,953
$21.09 P/Share
|
|
Aug 09
2021
|
Kevin Rakin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
79,136
+25.91%
|
$395,680
$5.74 P/Share
|
|
Aug 04
2021
|
Michael Rabinowitz Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Feb 26
2021
|
Leonard Sank Director |
SELL
Other acquisition or disposition
|
Indirect |
453,125
-100.0%
|
$1,359,375
$3.68 P/Share
|